We have developed an innovative intranasal powder formulation of Naloxone HCl + carrier, delivered via an FDA-approved, gold-standard nasal spray device. Leveraging our 20+ years of intranasal powder delivery expertise, our ambition is to exceed the bioavailability of existing liquid sprays in the opioid overdose space.

Our credible management team with expertise in pharma acquisition, licensing, IP, clinical research, product development, regulatory and manufacturing is supported by a heavy weight Scientific Advisory Board.

Our powder form intranasal Naloxone combines proven delivery science, regulatory alignment, and strong market demand. With early-stage IP secured and technical milestones achieved, this platform is positioned to capture meaningful market share and deliver a differentiated, higher-performing alternative to Narcan.

Armed with strong clinical results, we will be running a competitive process to achieve acquisition of our IP and all supportive knowledge & data.